Invesaro

Stocks Health care OTLK

NASDAQ · Health care

Outlook Therapeutics, Inc. (OTLK)

It posted a net loss of $61.1M. At June 30, 2026 it held $11.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 18, 2026.

What Outlook Therapeutics, Inc. does

Outlook Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker OTLK.

Revenue and profit by year

Revenue
FY18: $3.1M $3.1M FY18FY19: $8.1M $8.1M FY19FY25: $1.4M $1.4M FY25
Net income
FY18: -$30.1M -$30.1M FY18FY19: -$34.5M -$34.5M FY19FY20: -$35.2M -$35.2M FY20FY21: -$53.2M -$53.2M FY21FY22: -$66.1M -$66.1M FY22FY23: -$59M -$59M FY23FY24: -$75.4M -$75.4M FY24FY25: -$62.4M -$62.4M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$1.4M-$67.1M-$62.4M-$1.79n/a
2024n/a-$71.7M-$75.4M-$4.06n/a
2023n/a-$53.1M-$59M-$4.72n/a
2022n/a-$63.1M-$66.1M-$6.10n/a
2021n/a-$51.7M-$53.2M-$6.88n/a
2020n/a-$36.8M-$35.2M-$13.18n/a

Latest SEC filings

What Outlook Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 18, 2026
  2. August 27, 2026
  3. August 19, 2026
  4. August 18, 2026
    Quarterly report 10-Q · period to June 30, 2026
  5. August 17, 2026
  6. August 14, 2026
  7. August 14, 2026
  8. August 14, 2026
  9. August 14, 2026
  10. August 12, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 2, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about OTLK

What does Outlook Therapeutics, Inc. do?

Outlook Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker OTLK.

Is Outlook Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $61.1M.

When did Outlook Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 18, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 18, 2026.

Similar companies

Follow OTLK

Get an email when Outlook Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow OTLK: get an email when it files

Where the numbers come from

Financial figures are the values Outlook Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.